Angiodynamics (ANGO) EBITDA (2010 - 2026)

Angiodynamics (ANGO) has reported EBITDA for 17 consecutive years, with -$10.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 76.14% year-over-year to -$10.2 million; the trailing twelve-month figure through May 2026 stood at -$39.9 million (changed 0.07% YoY), and the FY2026 full-year result was -$39.9 million, changed 0.07% from the prior year.
• EBITDA rose to -$10.2 million in Q2 2026 per ANGO's latest filing, from -$13.0 million in the prior quarter.
• Across five years, EBITDA topped out at $35.0 million in Q3 2023 and bottomed at -$199.9 million in Q1 2024.
• Historically, EBITDA has averaged -$18.6 million across 5 years, with a median of -$10.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: EBITDA soared 363.36% in 2023, then tumbled 2138.98% in 2024.
• Over 5 years, EBITDA stood at -$8.1 million in 2022, then sank by 61.68% to -$13.1 million in 2023, then rose by 15.44% to -$11.1 million in 2024, then jumped by 44.79% to -$6.1 million in 2025, then plunged by 66.45% to -$10.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$10.2 million, -$13.0 million, and -$6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.